RMDA: Downtrend Channel Correction Sets Up Rebound Near 5.90 EGPTenth of Ramadan Pharmaceutical Industries & Diagnostic-RamedaEGX_DLY:RMDAmnmabroukw36ix📊 RMDA: Downtrend Channel Correction Sets Up Rebound Near 5.90 EGP Support 💊 🏛️ Fundamentals: 📈 Strengths and Catalysts: Rameda operates 3 standalone factories with 20 production lines in 10th of Ramadan City. 🏭 Company markets over 100 therapeutic products locally and exports across 10+ MENA and African markets. 🌍 Expanding high-margin export revenue provides solid operational strength. 💵 Pending EDA price adjustment approvals across 15+ high-volume molecules serve as a 2H26 catalyst. 🚀 ⚠️ Weaknesses and Risks: Free cash flow yield screens negative as a statistical outlier due to inventory and receivable drags. 📊 Primary risk involves API import cost spikes from EGP devaluation before EDA approves price hikes. 🌐 🧾 Shareholders and Free Float: Equinox Ventures Limited holds a controlling 46.22% anchor private equity stake. 🧾 Mutual funds and ETFs hold 3.85% across foreign and domestic institutional portfolios. 🏛️ Active market liquidity sits at a 49.93% public free float. 💧 Wholly owns Rawaat El-Mawaad in Saudi Arabia and Rameda Pharmaceuticals FZ-LLC in UAE. 🔑 🕌 Sharia Screen: Sharia status: Compliant. Non-compliant income ratio sits at 0.0%, below the 5.0% ceiling. 🟢 📈 The Pulse: Stock delivers strong performance with an 82.6% YTD return and an 86.7% 1Y return. 🚀 Price hit a 7.21 EGP triangle extension target and reached an ATH at 7.39 EGP before correcting. 📊 Current correction wave reflects broader weakness hitting all medical sector stocks. 📉 Buyers defended the 61.8% Fibonacci support level at 5.90 EGP today with a visible rebound. 🛡️ Breaking below 5.90 EGP support opens the door for a slide to main support at 5.11 EGP. 🛑 I am waiting for a clean breakout above the downtrend channel to take a new entry. ⏳ 🧱 The Key Structural Boundaries • Main Support: 5.11 EGP level. 🟢 • Historical Resistance / ATH: 7.39 EGP level. 🔴 • Strategy: Wait for confirmed downtrend channel breakout before entering. 📊 🎯 Verdict: Strong generic pharma portfolio and EDA price catalysts back long-term fundamentals. 🏛️ I remain patient on the sidelines until price breaks out of the downtrend channel. 🟢 If you like my insights, follow and boost! 🙌💙🚀 🎁 $15 TradingView Discount: https://www.tradingview.com/pricing/?share_your_love=mnmabroukw36ix ✨💸🤑